Cancer treatment biotech AdvanCell injects $178 million Series C
Sydney clinical-stage radiopharmaceutical startup AdvanCell, which is developing innovative cancer therapeutics, has raised US$112 million (A$178m) in a Series C. The round was co-led by US-UK fund SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis. Additional support came from existing investor Morningside, alongside new investors Tenmile, Brandon Capital, and others. Founded in June 2019, AdvanCell was… Read more »